3 Largest Private Hospital Group, Radiology and Pathology Services Provider and Healthcare Technology Firm Stocks With a Strong Future Roadmap: Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene
- October 30, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene: ROE of 10.3% to 20.5% and FY22 to FY26 revenue CAGR of 14.6% to 20.7%. Prices as of 29 Oct 2026.
Quick Answer
The three hospital chain, scan and healthtech stocks to watch are Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene. Their return on equity ranges from 10.3% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.6% to 20.7%. Apollo Hospitals Enterprise has the highest return on equity at 20.5%, while Indegene has the fastest revenue growth at 20.7% a year. Prices are based on the 29 October 2026 close, and this article is educational, not investment advice.
Hospital chain, scan and healthtech stocks give investors a way to track businesses that sit close to everyday demand in India. Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene cover the largest private hospital group, a radiology and pathology services provider and a healthcare technology firm.
This list covers three hospital chain, scan and healthtech stocks with complete current figures: Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hospital Chain, Scan and Healthtech Stocks?
Hospital chain, scan and healthtech stocks are listed companies that run large hospital networks with pharmacy and diagnostics, provide scans and lab tests through government partnerships and their own centres and help drug and device makers with digital, medical and commercial services. Their earnings depend on patient volumes, test mix and client contracts.
Hospital Chain, Scan and Healthtech Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | 8,200 | 110,757 | 51.0 | 59.6 | 20.5 | 0.90 |
| Krsnaa Diagnostics | 497.95 | 1,615 | 16.6 | 58.4 | 10.3 | 0.55 |
| Indegene | 593.45 | 14,454 | 36.0 | 59.2 | 12.8 | 0.05 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing hospital chain, scan and healthtech stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in hospital chain, scan and healthtech stocks can use the coming numbers to test whether growth is holding.
Why Do Hospital Chain, Scan and Healthtech Stocks Have a Strong Roadmap in India?
Hospital chain, scan and healthtech stocks have a strong roadmap in India because rising health awareness, wider insurance cover and growing use of digital health services keep widening the market for these care providers.
- Patient demand. Insurance cover brings more people to care.
- Test volumes. Scans and lab tests grow with screening.
- Digital health. Drug makers adopt data led services.
Why Apollo Hospitals Enterprise Features Among These Hospital Chain, Scan and Healthtech Stocks
Among the hospital chain, scan and healthtech stocks on this list, Apollo Hospitals Enterprise is India’s largest private healthcare group, running a network of hospitals along with a pharmacy chain, diagnostics, primary care clinics and a digital health platform.
Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%.
In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6.
Roadmap: The company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
What to watch: Track bed additions and occupancy and the growth of the pharmacy and digital health businesses.
Why Krsnaa Diagnostics Features Among These Hospital Chain, Scan and Healthtech Stocks
Among the patient care shares on this list, Krsnaa Diagnostics provides radiology and pathology services through partnerships with government hospitals and through its own diagnostic centres across many states.
In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%.
Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4.
Roadmap: The company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.
What to watch: Track new contract wins, test volumes and the rollout of advanced imaging.
Why Indegene Features Among These Hospital Chain, Scan and Healthtech Stocks
Among the three companies on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.
The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2.
Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore.
Roadmap: The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.
What to watch: Monitor client additions, platform adoption and growth in artificial intelligence services.
Apollo Hospitals Enterprise vs Krsnaa Diagnostics vs Indegene on Key Financials
The table below sets the three hospital chain, scan and healthtech stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise | 14,741 | 25,420 | 14.6% | 2,003 | 7.9% |
| Krsnaa Diagnostics | 470 | 816 | 14.8% | 101 | 12.4% |
| Indegene | 1,690 | 3,582 | 20.7% | 401 | 11.2% |
Apollo Hospitals Enterprise posts the highest return on equity in this group at 20.5%. Apollo Hospitals Enterprise has the largest FY26 revenue at Rs 25,420 crore, and Indegene shows the fastest revenue growth with a 20.7% compound annual rate. A useful habit with hospital chain, scan and healthtech stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Apollo Hospitals Enterprise | 5,882 | 7,092 | 20.6% |
| Krsnaa Diagnostics | 197 | 243 | 23.3% |
| Indegene | 783 | 1,092 | 39.5% |
Key Risks to Check Before Investing in Hospital Chain, Scan and Healthtech Stocks
Every theme carries risks that deserve a check before any decision. For these hospital chain, scan and healthtech stocks, the main points are: Long-term patient care shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Test volumes. Footfall and test mix can vary with seasons.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hospital chain, scan and healthtech stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hospital Chain, Scan and Healthtech Stocks
Hospital chain, scan and healthtech stocks work best when investors track growth, valuation and return on equity side by side. Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene each have a clear plan to grow. Based on the 29 October 2026 close, Apollo Hospitals Enterprise trades at Rs 8,200, Krsnaa Diagnostics at Rs 497.95 and Indegene at Rs 593.45. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these hospital chain, scan and healthtech stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track hospital chain, scan and healthtech stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hospital chain, scan and healthtech stocks?
Ans. Hospital chain, scan and healthtech stocks are listed companies that run large hospital networks with pharmacy and diagnostics, provide scans and lab tests through government partnerships and their own centres and help drug and device makers with digital, medical and commercial services. Their earnings depend on patient volumes, test mix and client contracts. This list looks at three of them, Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.
Which hospital chain, scan and healthtech stocks are covered in this list?
Ans. This list covers Apollo Hospitals Enterprise, Krsnaa Diagnostics and Indegene. Based on the 29 October 2026 close, Apollo Hospitals Enterprise traded at Rs 8,200, Krsnaa Diagnostics at Rs 497.95 and Indegene at Rs 593.45. Their return on equity ranges from 10.3% to 20.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 14.6% to 20.7%.
Why do hospital chain, scan and healthtech stocks have a strong future roadmap in India?
Ans. Hospital chain, scan and healthtech stocks have a strong roadmap in India because rising health awareness, wider insurance cover and growing use of digital health services keep widening the market for these care providers. The main drivers are as follows. Patient demand. Insurance cover brings more people to care. Test volumes. Scans and lab tests grow with screening. Digital health. Drug makers adopt data led services. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Apollo Hospitals Enterprise performed financially?
Ans. Revenue rose from Rs 14,741 crore in FY22 to Rs 25,420 crore in FY26, a compound annual growth rate of 14.6%. Net profit grew from Rs 1,101 crore in FY22 to Rs 2,003 crore in FY26, which works out to a compound annual growth rate of 16.1%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 7,092 crore, while net profit rose 38.4% to Rs 610 crore. The company has a return on equity of 20.5%, a debt to equity ratio of 0.90 and a market capitalisation of Rs 110,757 crore. The stock trades at a P/E of 51.0, below the industry P/E of 59.6. Looking ahead, the company is adding hospital beds in proven cities while growing its pharmacy and digital businesses, which broaden its reach beyond inpatient care. A strong brand in complex treatment and a wide patient base support steady occupancy.
How has Krsnaa Diagnostics performed financially?
Ans. Revenue rose from Rs 470 crore in FY22 to Rs 816 crore in FY26, a compound annual growth rate of 14.8%. Net profit grew from Rs 68.4 crore in FY22 to Rs 101 crore in FY26, which works out to a compound annual growth rate of 10.4%. In the June 2026 quarter, revenue grew 23.3% year on year to Rs 243 crore. The company has a return on equity of 10.3%, a debt to equity ratio of 0.55 and a market capitalisation of Rs 1,615 crore. The stock trades at a P/E of 16.6, below the industry P/E of 58.4. Looking ahead, the company is winning new public sector contracts and adding advanced imaging services, which widens its patient reach. Growing demand for affordable diagnostics supports volumes.
How has Indegene performed financially?
Ans. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.
What risks should investors check before buying hospital chain, scan and healthtech stocks?
Ans. Investors should check a few risks before buying hospital chain, scan and healthtech stocks. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Test volumes. Footfall and test mix can vary with seasons. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hospital chain, scan and healthtech stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
